Govinda Bhisetti is a Principal Investigator and Head of Computational Chemistry department at Biogen. His joined Biogen in 2014.
Govinda got his Ph. D. from Indian Institute of Science, Bangalore in 1986. He moved to Scripps Research Institute, La Jolla, CA in 1987 to do to post-doctoral research. His work at Scripps involved use of Cray XMP supercomputer to simulate protein-ligand interactions and design novel inhibitors. From there, he went to work at Vertex Pharmaceuticals Inc. in 1990 and worked in the Computational Sciences department for 22+ years where he led molecular modeling and drug design efforts on several drug discovery projects.
His research at Vertex led to the discovery of three FDA approved drugs: two AIDS drugs, Agenerase (amprenavir) and Lexiva (fosamprenavir), and one Hepatitis C drug, Incivek (Telaprevir). He is a co-inventor of these drugs and named inventor on 26 patents. He published 72 research papers including review articles and book chapters.
His current activities include application of state of the art computational methods in the discovery of novel drugs for neurodegenerative and neuroinflammatory diseases.